IVA Stock Overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Inventiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.16 |
| 52 Week High | €4.84 |
| 52 Week Low | €1.88 |
| Beta | 0.96 |
| 1 Month Change | -9.73% |
| 3 Month Change | -11.13% |
| 1 Year Change | 30.64% |
| 3 Year Change | -71.58% |
| 5 Year Change | 26.20% |
| Change since IPO | -63.23% |
Recent News & Updates
Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking
Mar 19
Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S
Jan 16Recent updates
Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking
Mar 19Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S
Jan 16Analyst Forecasts Just Became More Bearish On Inventiva S.A. (EPA:IVA)
May 20Pinning Down Inventiva S.A.'s (EPA:IVA) P/S Is Difficult Right Now
May 05Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)
Apr 01Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt
Jun 15Here's Why Inventiva S.A.'s (EPA:IVA) CEO May Deserve A Raise
Apr 11Did Business Growth Power Inventiva's (EPA:IVA) Share Price Gain of 251%?
Mar 19Here's What Inventiva S.A.'s (EPA:IVA) Shareholder Ownership Structure Looks Like
Jan 29
Is Inventiva's (EPA:IVA) 223% Share Price Increase Well Justified?
Dec 07Shareholder Returns
| IVA | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -5.5% | -1.4% | -0.1% |
| 1Y | 30.6% | -13.0% | 1.3% |
Return vs Industry: IVA exceeded the French Biotechs industry which returned -13% over the past year.
Return vs Market: IVA exceeded the French Market which returned 1.3% over the past year.
Price Volatility
| IVA volatility | |
|---|---|
| IVA Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: IVA has not had significant price volatility in the past 3 months.
Volatility Over Time: IVA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 122 | Frederic Cren | www.inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Inventiva S.A. Fundamentals Summary
| IVA fundamental statistics | |
|---|---|
| Market cap | €164.09m |
| Earnings (TTM) | -€110.43m |
| Revenue (TTM) | €23.16m |
7.1x
P/S Ratio-1.5x
P/E RatioIs IVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVA income statement (TTM) | |
|---|---|
| Revenue | €23.16m |
| Cost of Revenue | €1.02m |
| Gross Profit | €22.15m |
| Other Expenses | €132.57m |
| Earnings | -€110.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | -2.12 |
| Gross Margin | 95.61% |
| Net Profit Margin | -476.73% |
| Debt/Equity Ratio | -148.3% |
How did IVA perform over the long term?
See historical performance and comparison